Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
Rhea-AI Summary
Harmony Biosciences (Nasdaq: HRMY) will report its second quarter 2026 financial results on Tuesday, August 4, 2026, before U.S. market open. The company will host a conference call and live webcast that day at 8:30 a.m. ET for investors and analysts.
Positive
- None.
Negative
- None.
News Market Reaction – HRMY
In the Jul 21 session, HRMY gained 9.97%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.9% during that session. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Earnings date notice | Neutral | +0.3% | Scheduled Q1 2026 results and conference call for May 7 |
| Feb 10 | Earnings date notice | Neutral | +2.3% | Scheduled Q4 and full-year 2025 results for February 24 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Both tag-matched earnings-date notices were followed by positive 24-hour moves of 0.34% and 2.29%, with an average move of 1.31%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results.
To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMYQ226. It is recommended that you dial in at least 10 minutes prior to the call.
The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.
Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
